Nuvilex Comprehensive Analyst Report Answers Vital Questions for Shareholders, by BrokerBank Securities, Inc.
- Wednesday, February 26, 2014, 7:00
- Finance
- Add a comment
NEW YORK, Feb. 26, 2014 /PRNewswire/ — Nuvilex, Inc. (OTCQB: NVLX) owns exclusive rights to a cancer treatment platform that has successfully completed Phase 2 clinical trials for inoperable pancreatic cancer. Nuvilex also owns rights to the same platform to treat diabetes, and the…
Source: http://www.prnewswire.com/news-releases/nuvilex-comprehensive-analyst-report-answers-vital-questions-for-shareholders-by-brokerbank-securities-inc-247231821.html
About the Author
adminasapcorp has written 39635 stories on this site.